StockMarketWire.com - Respiratory drug developer Synairgen swung to an annual loss as it ramped up R&D spending.

Pre-tax losses for the year through December amounted to £4.1m, compared to profits of £1.6m on-year.

'2018 was a year of excellent operational progress for Synairgen,' chairman Simon Shaw said.

'We were particularly pleased to advance our inhaled IFN-beta programme into a clinical trial to treat or prevent exacerbations of COPD and to increase the scope of the trial to support future partnering activity.'

'We were also pleased that our partner Pharmaxis announced completion of the three-month toxicology studies and await further steps in the advancement of this opportunity.'

'We look forward to continued progress in 2019.'


At market close: [LON:SNG] Synairgen PLC share price was -0.25p at 16p



Story provided by StockMarketWire.com